不对称二甲基精氨酸、心血管疾病与糖尿病

ADMA, cardiovascular disease and diabetes.

作者信息

Krzyzanowska Katarzyna, Mittermayer Friedrich, Wolzt Michael, Schernthaner Guntram

机构信息

Department of Internal Medicine I, Rudolfstiftung Hospital, Vienna, Austria.

出版信息

Diabetes Res Clin Pract. 2008 Dec 15;82 Suppl 2:S122-6. doi: 10.1016/j.diabres.2008.09.024. Epub 2008 Oct 30.

DOI:10.1016/j.diabres.2008.09.024

PMID:18973964

Abstract

The endogenous competitive nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) is an emerging risk marker for future cardiovascular events. Elevated ADMA concentrations have been described in patients with an adverse cardiovascular risk profile. Recently, various studies investigated the independent role of ADMA as a cardiovascular risk predictor in several patient cohorts. In addition, ADMA might not only be a risk marker but also a causative factor for cardiovascular disease. This review summarizes the literature on the relationship between ADMA, cardiovascular disease and diabetes.

摘要

内源性竞争性一氧化氮合酶抑制剂不对称二甲基精氨酸（ADMA）是未来心血管事件的一个新出现的风险标志物。心血管风险不良的患者中已发现ADMA浓度升高。最近，多项研究调查了ADMA在多个患者队列中作为心血管风险预测指标的独立作用。此外，ADMA可能不仅是一种风险标志物，还是心血管疾病的一个致病因素。本综述总结了关于ADMA、心血管疾病和糖尿病之间关系的文献。